Results 251 to 260 of about 2,229,234 (312)
Baricitinib as Salvage Therapy for Multidrug‐Resistant Chronic Graft‐Versus‐Host Disease
MedComm, Volume 7, Issue 11, November 2026.
Zhuo‐Yu An +9 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hematology, 2002
AbstractThis is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic leukemia (ALL).Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches, prognostic factors, risk stratification, and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies ...
Dieter, Hoelzer +7 more
openaire +4 more sources
AbstractThis is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic leukemia (ALL).Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches, prognostic factors, risk stratification, and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies ...
Dieter, Hoelzer +7 more
openaire +4 more sources
Clinics in Laboratory Medicine, 2000
Over the last two decades, great strides have been made in the treatment of acute lymphoblastic leukemia (ALL). This progress has been paralleled by advances in diagnosis. In addition to morphology and cytochemistry, the diagnostic and prognostic importance of immunophenotypic and genetic features is becoming increasingly apparent. This article reviews
D C, Farhi, N S, Rosenthal
openaire +2 more sources
Over the last two decades, great strides have been made in the treatment of acute lymphoblastic leukemia (ALL). This progress has been paralleled by advances in diagnosis. In addition to morphology and cytochemistry, the diagnostic and prognostic importance of immunophenotypic and genetic features is becoming increasingly apparent. This article reviews
D C, Farhi, N S, Rosenthal
openaire +2 more sources
Pediatric Clinics of North America, 1997
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire +2 more sources
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire +2 more sources

